What is mTilda?
mTilda offers a comprehensive Histocompatibility and Immunogenics (HLA) laboratory information management system designed for enterprise-level deployment. The platform features scalable HLA-specific modules that manage specimen workflow, patient and data management, inventory control, reagent vendor connectivity, and institutional EMR/LIS interoperability. Founded in 2000 and headquartered in Houston, Texas, mTilda aims to streamline complex laboratory operations through its robust and customizable reporting capabilities. The company's focus on critical healthcare IT infrastructure positions it as a key player in the medical diagnostics software market.
How much funding has mTilda raised?
mTilda has raised a total of $750K across 1 funding round:
Other Financing Round
$750K
Other Financing Round (2021): $750K with participation from Golden Section Venture Capital
Key Investors in mTilda
Golden Section Venture Capital
Golden Section Venture Capital is identified as a backer, suggesting a focus on technology ventures with potential for significant growth and market impact.
What's next for mTilda?
The recent major strategic investment in mTilda signals a pivotal phase for the company, likely enabling accelerated product development, market expansion, and enhanced interoperability features. With a substantial total funding amount of $750K, mTilda is well-positioned to scale its operations and further solidify its market presence. Future strategic initiatives may include deeper integration with healthcare systems, expanding its module offerings, and potentially exploring new therapeutic areas within immunogenetics. This capital infusion is expected to drive innovation and reinforce mTilda's competitive edge in the enterprise LIMS landscape.
See full mTilda company page
